Dr. Keel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-228-1000
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2002 - 2006
- University of MinnesotaResidency, Internal Medicine, 1999 - 2002
- University of Minnesota Medical SchoolClass of 1999
Certifications & Licensure
- WA State Medical License 2002 - 2025
- MN State Medical License 2003 - 2004
Publications & Presentations
PubMed
- 100 citationsDistinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.Alyssa L. Kennedy, Kasiani C. Myers, James Bowman, Christopher J. Gibson, Nicholas D. Camarda
Nature Communications. 2021-02-26 - 58 citationsNCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Peter L Greenberg, Richard M Stone, Aref Al-Kali, John M Bennett, Uma Borate
Journal of the National Comprehensive Cancer Network. 2022-02-01 - 7 citationsRestoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.Michelle C Krutein, Matthew R. Hart, Donovan J. Anderson, Jasmin Jeffery, Andriana G. Kotini
Blood Advances. 2021-02-09
Abstracts/Posters
- Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myel...Sioban B. Keel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid ...Sioban Keel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Sioban B. Keel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: